- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04885959
Traditional Asian Diet and Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Infant's Allergy Development (PPBe)
The Effects of Traditional Asian Diet on Gut Microbiome and Metabolome in Healthy Volunteers and Pregnancy on Subsequent Infant's Allergy Development
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kelantan
-
Kota Bharu, Kelantan, Malaysia, 16150
- Hospital Universiti Sains Malaysia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Malaysian and of the Malay ethnicity
- Living in Kelantan for at least 5 years
- Age 18 to 40 years
- The lower limit of ≥16th weeks and the upper limit of <20th week of gestation during enrollment to allow at least 20 weeks of dietary intervention prior to delivery. The gestational age was based on the last menstrual period (LMP) or early ultrasound examination
- Singleton pregnancy
- History of personal and family history of allergy (presence of reported or doctor-diagnosed allergic disease including asthma, eczema, food allergy, or allergy rhinitis) in participants, their partners or in their previous child or pregnancy.
- In attendance of antenatal clinic at Hospital USM or Klinik Kesihatan (Kota Bharu/Kubang Kerian/Pengkalan Chepa)
- Living area within 10 km radius of Kota Bharu, Kelantan
- Consent to participate
Exclusion Criteria:
- Significant present or having past medical history of chronic disease for example bowel, cancer disease, systemic lupus erythematosus (SLE), chronic kidney disease, heart failure, stroke, haematological malignancy, and chronic obstructive pulmonary disease.
- Significant psychiatric history including major depression and other psychotic disorders.
- Significant present or past surgical history including bowel surgeries
- Significant presence of doctor-diagnosed short intestinal bacteria overgrowth (SIBO).
- Taking any medications which may disturb the gut microbiota or intestinal function, for example, antibiotics for the past 3 months, immunosuppressive drugs, opiates, anticoagulants and etc.
- Those who plan to move out from Kelantan after delivery which may affect the follow-up.
- Those who follow a vegetarian diet will also be excluded from participating.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Usual diet
In the pilot study among healthy volunteers, participant need to maintain their habitual diet for 4 weeks.
Meanwhile, in the large-scale study among pregnant women, participants are subjected to receive general dietary advice for healthy pregnancy from attended nurses or physician during their antenatal visits.
|
|
|
Experimental: Traditional Asian Diet
Participants will receive dietary intervention on a traditional Asian diet which diet consists of high fiber, moderate protein, and low fat and with the inclusion of local probiotics and prebiotics food sources which are known to enhance gut health by fostering the gut colonization of beneficial bacteria and promoting the production of SCFA. During the pilot phase the diet is given for four weeks. Meanwhile, the intervention among pregnant mothers, the intervention is given for 20 weeks considering the nature of the availability of pregnant mothers being recruited where most of them (low risk pregnancy) were given their first clinic appointment at 16 weeks of gestational age. |
The personalized traditional Asian diet will be formulated based on dietary components of a typical Asian diet characterized by high intake of fruits and vegetables, whole grains, legumes, nuts, seeds, soy foods and herbs and spices; moderate intake of fish, poultry, eggs, healthy cooking oils, yogurt or functional foods and low intake of meats and sweets (Ismail et al., 2020).
The diet design also considering the recommendation of personalized dietary approach by including the element of individual preferences, requirement, cultural preferences, affordability and foods availability to facilitate the adherence and response to the diet.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maternal gut microbiome composition before and after intervention
Time Frame: 20 weeks
|
Maternal stool samples will be collected at three pre-determined intervals (baseline (week 16), week-28 and week-36 gestation.
The gut microbiota composition will be examined using the 16s rRNA sequencing.
The alpha (Shannon, Simpson and Evenness Indices) and beta diversity of the gut microbiota will be compared within and between groups.
|
20 weeks
|
|
Maternal stool metabolome concentration of short chain fatty acids (SCFA) before and after intervention
Time Frame: 20 weeks
|
Maternal stool samples will be collected at three pre-determined intervals (baseline (week 16), week-28 and week-36 gestation.
The changes in stool SCFA concentration in (umol/g) will analyzed using the gas chromatography - mass spectrometry (GC-MS).
The concentration (umol/g) be compared within and between groups.
|
20 weeks
|
|
Incidence of allergy development in the delivered infants and its correlation with maternal gut microbiome during pregnancy.
Time Frame: 12 months
|
Symptoms perceived by parents/caregivers will be asked during postnatal follow-ups at day day-28, 3, 6 and 12 months of age using a validated questionnaire, the Comprehensive Early Childhood Allergy Questionnaire (CECAQ) (Minasyan A. et al.,2015).
The results are then correlated with the maternal gut microbiome composition during pregnancy which was first being examined through the 16S rRNA sequencing analysis.
|
12 months
|
|
Incidence of allergy development in the delivered infants and its correlation with maternal stool metabolome during pregnancy.
Time Frame: 12 months
|
Symptoms perceived by parents/caregivers will be asked during postnatal follow-ups at day day-28, 3, 6 and 12 months of age using a validated questionnaire, the Comprehensive Early Childhood Allergy Questionnaire (CECAQ) (Minasyan A. et al.,2015).
The results are then correlated with the maternal gut microbiome composition during pregnancy which was first being examined through the 16S rRNA sequencing analysis.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Infant's gut microbiome composition at neonatal age and its correlation with allergy development
Time Frame: 12 months
|
Infant's stool samples collected during the neonatal age (day-0 to day-28 post delivery).
The stool DNA will be extracted to examine the gut microbiome composition through 16s rRNA sequencing.
The alpha (Shannon, Simpson and Evenness Indices) and beta diversity of the gut microbiota will be correlate with the incidence of allergy.
|
12 months
|
|
Infant's stool metabolome of the short-chain fatty acids (SCFA) concentration during neonatal age and its correlation with allergy development
Time Frame: 12 months
|
Infant's stool samples collected during the neonatal age (day-0 to day-28 post delivery).
The stool concentration of the SCFA measured in umol/g will be analyzed using the gas chromatography-mass spectrometry (GC-MS).
The concentration of the SCFA (in umol/g) will be correlate with the incidence of allergy.
|
12 months
|
|
Infant's immune functions and allergy development
Time Frame: 12 months
|
Infant's immune function (measured by concentration of interleukin-10/IL-10, and transforming growth factor-beta/TGF-B).
The plasma will be assayed IL-10 and transforming growth factor beta (TGF-β) using the ELISA kits following the manufacturer and the concentration measured in ng/mL.
The concentrations IL-10 and TGF-Beta (ng/mL) will be further examined its correlation with allergy development in infants.
|
12 months
|
|
Infant's gut barrier and allergy development
Time Frame: 12 months
|
Infant's gut barrier will be measured through the serum FABP2, a marker of intestinal integrity (Vreugdenhil et al., 2011).
The plasma will be assayed using the Human FABP2 ELISA kit following manufacturer instructions.
The concentration of the FABP2 measured in ng/mL will be further examined its correlation with allergy development in infants.
|
12 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The changes on gut microbiome composition in healthy volunteers before and after 4 weeks dietary intervention.
Time Frame: 4 weeks
|
Stool samples will be collected at three pre-determined intervals (baseline, week-2 and week-4) during study period.
The gut microbiota composition will be examined using the 16s rRNA sequencing.
The alpha (Shannon, Simpson and Evenness Indices) and beta diversity of the gut microbiota will be compared within and between groups.
|
4 weeks
|
|
The changes on stool metabolome of shiort chain fatty cids (SCFA) composition in healthy volunteers before and after 4 weeks dietary intervention.
Time Frame: 4 weeks
|
Stool samples will be collected at three pre-determined intervals (baseline, week-2 and week-4) during study period.
The stool SCFA concentration in (umol/g) will analyzed using the gas chromatography - mass spectrometry (GC-MS).
The changes in SCFA concentration (umol/g) be compared within and between groups.
|
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: NUR-FAZIMAH SAHRAN, Universiti Sains Malaysia
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- USM/JEPeM/20120611
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Food Hypersensitivity
-
Fundación Pública Andaluza para la Investigación...Institute of Biomedical Research in Málaga (IBIMA)Not yet recruiting
-
University Hospital, AngersUnknown
-
Fundación Pública Andaluza para la Investigación...Not yet recruiting
-
Austin HealthRoyal Melbourne Hospital, AustraliaRecruitingFood AllergiesAustralia
-
Federico II UniversityCompleted
-
University of Missouri-ColumbiaTerminated
-
Stanford UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Harvard School... and other collaboratorsCompletedHypersensitivity | Peanut Hypersensitivity | Peanut Allergy | Food Allergy | Hypersensitivity, FoodUnited States
-
Stanford UniversityRecruitingFood AllergyUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoNational Institute of Allergy and Infectious Diseases (NIAID)CompletedFood Allergy Peanut | Food Allergy in InfantsUnited States
-
University of ZurichCompletedHypersensitivity, FoodSwitzerland
Clinical Trials on Traditional Asian Diet
-
Peking University Third HospitalNot yet recruiting
-
Peking Union Medical College HospitalGuangdong Provincial Hospital of Traditional Chinese Medicine; Peking University... and other collaboratorsRecruitingFunctional Hypothalamic AmenorrheaChina
-
Peking Union Medical College HospitalShandong University; Guangdong Provincial Hospital of Traditional Chinese Medicine and other collaboratorsNot yet recruitingInfertility | Diminished Ovarian Reserve (DOR)China
-
Fujian Medical University Union HospitalNot yet recruiting
-
Henan University of Traditional Chinese MedicineThe First Affiliated Hospital of Zhengzhou University; China-Japan Friendship... and other collaboratorsNot yet recruiting
-
Fudan UniversityNot yet recruitingMoyamoya Disease | Moyamoya SyndromeChina
-
University of Alabama at BirminghamNot yet recruitingDiabetic Macular Edema (DME)United States
-
Peking University Cancer Hospital & InstituteNot yet recruiting
-
The Third Xiangya Hospital of Central South UniversityMaternity and Child Health Hospital of Changsha; Changsha Jiangwan Maternity...Recruiting
-
Peking Union Medical College HospitalRecruitingDiminished Ovarian Reserve (DOR)China